The findings in prostate cancer contrast to our observations in urothelial carcinoma, in which HER2 expression was present more frequently, with HER2 ≥2+ and 3+ expressions observed in 20% and 15% of patients, respectively. This evidence concerns the gene ERBB2 and prostate carcinoma.